Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib DDI Study with CYP3A4 and CYP2C9 Substrates
NCT03291288Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Sep 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of pexidartinib in tenosynovial giant cell tumor (TGCT), gastrointestinal stromal tumor (GIST), melanoma and 1 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Concentration (Cmax) for Midazolam, Maximum Concentration (Cmax) for Tolbutamide and 5 more. Started Feb 2018; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)gastrointestinal stromal tumor (GIST)melanomasolid tumor
Beyond the preview
Go deeper on NCT03291288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291288.